AICDA and diffuse large B-cell lymphoma: Multivariate analysis indicated that positive AID expression was associated with shorter overall survival (OS) specifically among patients receiving a rituximab-containing regimen, with a hazard ratio of 10.39 (95% CI: 1.93-55.96; p = 0.006).<h4>Conclusion</h4>The significant prognostic value of AID in the DLBCL subgroup treated with rituximab-but not in the general DLBCL population or in those not receiving rituximab-underscores the potential relevance of AID expression in DLBCL management and treatment decisions.